NCT03452540View on ClinicalTrials.gov

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

June 19, 2019

Study Completion Date

March 31, 2020

Conditions
Severe Acute Decompensated Alcoholic Hepatitis
Interventions
DRUG

1000mg DS102 (BID)

Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.

Trial Locations (8)

23602

Bon Secours Liver Institute of Richmond and Bon Secours Liver Institute of Hampton Roads, Newport News

29425

Medical University of South Carolina, Charleston

33136

Schiff Center for Liver Diseases (University Hospital Miami), Miami

33331

Cleveland Clinic Florida, Miami

66160

Kansas University Medical Center, Kansas City

02215

Beth Israel Deaconess Medical Center, Boston

Unknown

Batumi Referral Hospital, Batumi

Saint Nikolozi Surgery Center, Kutaisi

Sponsors

Lead Sponsor

Afimmune
All Listed Sponsors
lead

Afimmune

INDUSTRY

NCT03452540 - Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis | Biotech Hunter | Biotech Hunter